Adjunctive Sirolimus and Oseltamivir Versus Oseltamivir Alone for Treatment of Influenza
Status:
Not yet recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
Seasonal influenza epidemics are important causes of mortality and morbidity. Cytokine
dysregulation, with high levels of pro-inflammatory cytokines, occurs in patients with severe
influenza A(H1N1)pdm09 virus infection, A(H5N1) infection, and A(H7N9) infection. We aim to
investigate the effects of adjunctive sirolimus in adults hospitalized with influenza A or B
infections involving the lower respiratory tract.